Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 06-Sep-12 4:17 PM View:  | Warburg Pincus Private Equi... Director 10% Owner | Allos Therapeutics, Inc. (ALTH) | 05-Sep-12 | Disposition (change in control) | 26,124,400 | $1.82 | $47,546,500.00 | (100%) 26.12M to 0 | (1%) |
| 05-Sep-12 4:43 PM View: | Bennett Bruce K Jr VP, Pharmaceutical Operations | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 148,482 | $1.82 | $270,237.00 | (100%) 148.48K to 0 | (< 1%) |
| 05-Sep-12 4:48 PM View: | Schick Michael E VP, Sales and Marketing | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 285,113 | $1.82 | $518,906.00 | (100%) 285.11K to 0 | (< 1%) |
| 05-Sep-12 4:54 PM View: | Stout David M Director | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 35,000 | $1.82 | $63,700.00 | (100%) 35.0K to 0 | (< 1%) |
| 05-Sep-12 4:46 PM View: | Goldsmith Bruce A SVP, Corporate Development | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 346,933 | $1.82 | $631,418.00 | (100%) 346.93K to 0 | (< 1%) |
| 05-Sep-12 4:41 PM View: | Berns Paul L Chief Executive Officer | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 1,233,320 | $1.82 | $2,244,650.00 | (100%) 1.23M to 0 | (< 1%) |
| 05-Sep-12 4:50 PM View: | Hoffman Stephen J Director | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 92,000 | $1.82 | $167,440.00 | (16%) 565.67K to 473.67K | (< 1%) |
| 05-Sep-12 4:44 PM View: | Clark Dsvid C VP, Finance | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 207,114 | $1.82 | $376,948.00 | (100%) 207.11K to 0 | (< 1%) |
| 05-Sep-12 4:52 PM View: | Latts Jeffrey Director | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 55,000 | $1.82 | $100,100.00 | (100%) 55.0K to 0 | (< 1%) |
| 05-Sep-12 4:55 PM View: | Turner Joseph L Director | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 55,000 | $1.82 | $100,100.00 | (100%) 55.0K to 0 | (< 1%) |
| 05-Sep-12 4:47 PM View: | Morris Charles Q Chief Medical Officer | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 655,031 | $1.82 | $1,192,160.00 | (100%) 655.03K to 0 | (< 1%) |
| 05-Sep-12 4:50 PM View: | Hoffman Stephen J Director | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 473,671 | $1.82 | $862,081.00 | (100%) 473.67K to 0 | (< 1%) |
| 05-Sep-12 4:45 PM View: | Graboyes Marc H SVP, General Counsel | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 542,028 | $1.82 | $986,491.00 | (100%) 542.03K to 0 | (< 1%) |
| 05-Sep-12 4:53 PM View: | Leff Jonathan S Director | Allos Therapeutics, Inc. (ALTH) | 04-Sep-12 | Disposition (change in control) | 55,000 | $1.82 | $100,100.00 | (100%) 55.0K to 0 | (< 1%) |
| 13-Jul-12 4:40 PM View: | Schick Michael E VP, Sales and Marketing | Allos Therapeutics, Inc. (ALTH) | 11-Jul-12 | Market Sale (Planned) | 697 | $1.78 | $1,241.50 | (< 1%) 285.81K to 285.11K | < 1% |
| 30-Apr-12 4:58 PM View: | Morris Charles Q Chief Medical Officer | Allos Therapeutics, Inc. (ALTH) | 27-Apr-12 | Market Sale (Planned) | 7,970 | $1.81 | $14,426.50 | (1%) 673.29K to 665.32K | (< 1%) |
| 30-Apr-12 4:59 PM View: | Bennett Bruce K Jr VP, Pharmaceutical Operations | Allos Therapeutics, Inc. (ALTH) | 27-Apr-12 | Private Purchase | 1,104 | $1.22 | $1,341.91 | < 1% 147.38K to 148.48K | |
| 01-Mar-12 6:15 PM View: | Berns Paul L Chief Executive Officer | Allos Therapeutics, Inc. (ALTH) | 01-Mar-12 | Market Sale (Planned) | 21,532 | $1.48 | $31,815.70 | (2%) 1.25M to 1.23M | 1% |
| 01-Mar-12 6:15 PM View: | Clark Dsvid C VP, Finance | Allos Therapeutics, Inc. (ALTH) | 01-Mar-12 | Market Sale (Planned) | 3,385 | $1.50 | $5,073.44 | (2%) 210.5K to 207.11K | 3% |
| 01-Mar-12 6:12 PM View: | Schick Michael E VP, Sales and Marketing | Allos Therapeutics, Inc. (ALTH) | 01-Mar-12 | Market Sale (Planned) | 3,960 | $1.48 | $5,865.95 | (1%) 289.77K to 285.81K | (< 1%) |
| 01-Mar-12 6:13 PM View: | Graboyes Marc H SVP, General Counsel | Allos Therapeutics, Inc. (ALTH) | 01-Mar-12 | Market Sale (Planned) | 9,635 | $1.48 | $14,259.80 | (2%) 551.66K to 542.03K | 1% |
| 01-Mar-12 6:16 PM View: | Bennett Bruce K Jr VP, Pharmaceutical Operations | Allos Therapeutics, Inc. (ALTH) | 01-Mar-12 | Market Sale (Planned) | 3,025 | $1.50 | $4,522.38 | (2%) 150.4K to 147.38K | 2% |
| 01-Mar-12 6:14 PM View: | Goldsmith Bruce A SVP, Corporate Development | Allos Therapeutics, Inc. (ALTH) | 01-Mar-12 | Market Sale (Planned) | 4,473 | $1.50 | $6,690.27 | (1%) 351.41K to 346.93K | 2% |
| 01-Mar-12 6:12 PM View: | Schick Michael E VP, Sales and Marketing | Allos Therapeutics, Inc. (ALTH) | 29-Feb-12 | Market Sale (Planned) | 3,894 | $1.52 | $5,934.85 | (1%) 293.66K to 289.77K | 2% |
| 01-Mar-12 6:13 PM View: | Graboyes Marc H SVP, General Counsel | Allos Therapeutics, Inc. (ALTH) | 29-Feb-12 | Market Sale (Planned) | 9,425 | $1.52 | $14,365.60 | (2%) 561.09K to 551.66K | 4% |
| 01-Mar-12 6:16 PM View: | Bennett Bruce K Jr VP, Pharmaceutical Operations | Allos Therapeutics, Inc. (ALTH) | 29-Feb-12 | Market Sale (Planned) | 3,031 | $1.53 | $4,622.88 | (2%) 153.43K to 150.4K | 4% |
| 01-Mar-12 6:14 PM View: | Goldsmith Bruce A SVP, Corporate Development | Allos Therapeutics, Inc. (ALTH) | 29-Feb-12 | Market Sale (Planned) | 4,505 | $1.52 | $6,869.22 | (1%) 355.91K to 351.41K | 4% |
| 01-Mar-12 6:15 PM View: | Berns Paul L Chief Executive Officer | Allos Therapeutics, Inc. (ALTH) | 29-Feb-12 | Market Sale (Planned) | 21,163 | $1.52 | $32,235.50 | (2%) 1.28M to 1.25M | 4% |
| 01-Mar-12 6:15 PM View: | Clark Dsvid C VP, Finance | Allos Therapeutics, Inc. (ALTH) | 29-Feb-12 | Market Sale (Planned) | 3,388 | $1.52 | $5,164.67 | (2%) 213.89K to 210.5K | 4% |
| 01-Mar-12 6:13 PM View: | Morris Charles Q Chief Medical Officer | Allos Therapeutics, Inc. (ALTH) | 29-Feb-12 | Market Sale (Planned) | 10,155 | $1.52 | $15,478.30 | (1%) 683.45K to 673.29K | 2% |
| 01-Mar-12 6:12 PM View: | Schick Michael E VP, Sales and Marketing | Allos Therapeutics, Inc. (ALTH) | 28-Feb-12 | Grant | 135,545 | -- | -- | 86% 158.12K to 293.66K | |
| 01-Mar-12 6:15 PM View: | Berns Paul L Chief Executive Officer | Allos Therapeutics, Inc. (ALTH) | 28-Feb-12 | Grant | 573,506 | -- | -- | 82% 702.51K to 1.28M | |
| 01-Mar-12 6:13 PM View: | Graboyes Marc H SVP, General Counsel | Allos Therapeutics, Inc. (ALTH) | 28-Feb-12 | Grant | 222,266 | -- | -- | 66% 338.82K to 561.09K | |
| 01-Mar-12 6:16 PM View: | Bennett Bruce K Jr VP, Pharmaceutical Operations | Allos Therapeutics, Inc. (ALTH) | 28-Feb-12 | Grant | 43,862 | -- | -- | 40% 109.57K to 153.43K | |
| 01-Mar-12 6:14 PM View: | Goldsmith Bruce A SVP, Corporate Development | Allos Therapeutics, Inc. (ALTH) | 28-Feb-12 | Grant | 179,727 | -- | -- | 102% 176.18K to 355.91K | |
| 01-Mar-12 6:15 PM View: | Clark Dsvid C VP, Finance | Allos Therapeutics, Inc. (ALTH) | 28-Feb-12 | Grant | 99,779 | -- | -- | 87% 114.11K to 213.89K | |
| 01-Mar-12 6:13 PM View: | Morris Charles Q Chief Medical Officer | Allos Therapeutics, Inc. (ALTH) | 28-Feb-12 | Grant | 241,848 | -- | -- | 55% 441.6K to 683.45K | |
| 27-Feb-12 5:43 PM View: | Bennett Bruce K Jr VP, Pharmaceutical Operations | Allos Therapeutics, Inc. (ALTH) | 24-Feb-12 | Market Sale (Planned) | 1,469 | $1.55 | $2,277.10 | (1%) 111.04K to 109.57K | (2%) |
| 27-Feb-12 5:43 PM View: | Goldsmith Bruce A SVP, Corporate Development | Allos Therapeutics, Inc. (ALTH) | 24-Feb-12 | Market Sale (Planned) | 575 | $1.54 | $888.09 | (< 1%) 176.76K to 176.18K | (2%) |
| 27-Feb-12 5:44 PM View: | Berns Paul L Chief Executive Officer | Allos Therapeutics, Inc. (ALTH) | 24-Feb-12 | Market Sale (Planned) | 4,350 | $1.55 | $6,742.94 | (< 1%) 706.86K to 702.51K | (2%) |
| 27-Feb-12 5:42 PM View: | Clark Dsvid C VP, Finance | Allos Therapeutics, Inc. (ALTH) | 24-Feb-12 | Market Sale (Planned) | 595 | $1.55 | $922.31 | (< 1%) 114.7K to 114.11K | (2%) |
| 27-Feb-12 5:40 PM View: | Graboyes Marc H SVP, General Counsel | Allos Therapeutics, Inc. (ALTH) | 24-Feb-12 | Market Sale (Planned) | 1,380 | $1.54 | $2,125.34 | (< 1%) 340.2K to 338.82K | (3%) |
| 27-Feb-12 5:42 PM View: | Clark Dsvid C VP, Finance | Allos Therapeutics, Inc. (ALTH) | 23-Feb-12 | Market Sale (Planned) | 1,460 | $1.57 | $2,290.59 | (1%) 116.16K to 114.7K | (< 1%) |
| 27-Feb-12 5:40 PM View: | Graboyes Marc H SVP, General Counsel | Allos Therapeutics, Inc. (ALTH) | 23-Feb-12 | Market Sale (Planned) | 3,950 | $1.58 | $6,253.64 | (1%) 344.15K to 340.2K | < 1% |
| 27-Feb-12 5:43 PM View: | Bennett Bruce K Jr VP, Pharmaceutical Operations | Allos Therapeutics, Inc. (ALTH) | 23-Feb-12 | Market Sale (Planned) | 4,484 | $1.58 | $7,085.17 | (4%) 115.53K to 111.04K | < 1% |
| 27-Feb-12 5:41 PM View: | Schick Michael E VP, Sales and Marketing | Allos Therapeutics, Inc. (ALTH) | 23-Feb-12 | Market Sale (Planned) | 1,645 | $1.58 | $2,599.10 | (1%) 159.76K to 158.12K | (< 1%) |
| 27-Feb-12 5:43 PM View: | Goldsmith Bruce A SVP, Corporate Development | Allos Therapeutics, Inc. (ALTH) | 23-Feb-12 | Market Sale (Planned) | 2,500 | $1.58 | $3,958.00 | (1%) 179.26K to 176.76K | < 1% |
| 27-Feb-12 5:44 PM View: | Berns Paul L Chief Executive Officer | Allos Therapeutics, Inc. (ALTH) | 23-Feb-12 | Market Sale (Planned) | 9,100 | $1.56 | $14,196.00 | (1%) 715.96K to 706.86K | (1%) |
| 03-Jan-12 4:42 PM View: | Bennett Bruce K Jr VP, Pharmaceutical Operations | Allos Therapeutics, Inc. (ALTH) | 30-Dec-11 | Private Purchase | 1,173 | $1.21 | $1,415.81 | 1% 114.35K to 115.53K | |
| 15-Dec-11 4:33 PM View: | Desilva Nishan M Director | Allos Therapeutics, Inc. (ALTH) | 13-Dec-11 | Grant | 35,000 | -- | -- | 100% 0 to 35.0K |
